The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in NETs
Peter M. Anderson, MD, PhD , Cleveland Clinic, Cleveland, OH, discusses the findings of a Phase II study of the DRD2 antagonist/CIpP agonist ONC201 in neuroendocrine tumors (NETs). ONC201 was found to be well tolerated in adults with advanced NETs, particularly in paraganglioma patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
